Good afternoon :)
Switch to
Place Order

Shilpa Medicare Ltd

SHILPAMED
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,420 cr, stock is ranked 727
Moderate RiskStock is 2.39x as volatile as Nifty
300.750.45% (-1.35)
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,420 cr, stock is ranked 727
Moderate RiskStock is 2.39x as volatile as Nifty

Key Metrics

PE RatioPE RatioPB RatioPB RatioDividend YieldDiv. Yield
39.911.340.39%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.904.360.88%

Forecast & RatingsDetailed Forecast 

0%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. It is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. It supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.

Investor PresentationView older 

Nov 13, 2022

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

2019202020212022+0.79+0.92+0.99+1.17+0.11+0.16+0.15+0.06
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Related Party Transaction 
Announced OnNov 24, 2022

Shilpa Medicare Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Shilpa Medicare Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Transcript of Analysts/Institutional Investor Meet/Con. Call 
Announced OnNov 21, 2022

Shilpa Medicare Limited has informed the Exchange about Revised Transcript of Analysts/Institutional Investor Meet/Con. Call | Download

Shilpa Medicare Limited has informed the Exchange about Revised Transcript of Analysts/Institutional Investor Meet/Con. Call | Download

Cash Dividend 
Ex. DateSep 19, 2022

Final • Div/Share: ₹ 1.1

See all events